Therapeutic Uses of Eltrombopag and Romiplastin in Hepatitis C and Thrombocytopenia: A Review | Chapter 01 | Current Trends in Medicine and Medical Research Vol. 2
Eltrombopag,
is a thrombopoietin receptor agonist is used to increase the number of
platelets sufficient to decrease the risk of bleeding in thrombocytopenia
patient and also allow treatment with interferon and ribavirin in people
suffering with Hepatitis C. It is not used to increase platelets to a normal
level. Eltrombopag should not be used to treat people having low numbers of
platelets in patients other than immune thrombocytopenia or hepatitis C
patients. Eltrombopag is thrombopoietin receptor agonists and works by creating
the cells in the bone marrow to produce more platelets. It is an orally
bioavailable molecule with the potential to benefit patients with a wide range
of thrombocytopenias including thrombocytopenia secondary to chronic liver
disease. Chronic hepatitis C is a public health problem all over the world.
Eltrombopag can be a solution for many patients as it will allow for antiviral
therapy and getting a sustained virological response, but requires proper
monitoring to prevent possible bone marrow complications or liver failure
occurrence. Eltrombopag, and thrombopoietin can be used effectively in
treatment of thrombocytopenia and hepatitis C.
Biography of author(s)
Sachin Kumar Jain
Associate
Professor in the Department of Pharmacognosy, IPS Academy College of Pharmacy,
Indore MP India affiliated to RGPV technical University Bhopal MP India.
View Volume: https://doi.org/10.9734/bpi/ctmmr/v2
Comments
Post a Comment